Bone fragility emerges as a hidden crisis for families managing Duchenne muscular dystrophy, with new data revealing that more than half of affected teenagers develop osteoporosis by their 18th birthday. This finding challenges assumptions about pediatric bone health and highlights an urgent need for proactive skeletal monitoring in this vulnerable population.
Analysis of 408 boys with DMD receiving daily glucocorticoid therapy showed osteoporosis prevalence escalating dramatically with age: from 4.4% at age 5 to 20.9% at age 10, reaching 58.3% by age 18. The cohort averaged 8 years old and had been on steroids for nearly three years, starting treatment around age 6. Fracture rates reached 16.5% across long bones and vertebrae, underscoring the clinical consequences of progressive bone deterioration.
This Cincinnati Children's Hospital study fills a critical knowledge gap in DMD care, where bone health has historically taken a backseat to respiratory and cardiac complications. The steep age-related progression suggests a narrow window for intervention before irreversible skeletal damage occurs. While glucocorticoids remain essential for preserving muscle function and delaying wheelchair dependence, their bone-depleting effects create a therapeutic paradox that clinicians must now actively address.
The findings advocate for systematic bone density screening protocols starting in early childhood, potentially revolutionizing standard DMD care. Given that fractures can precipitate premature loss of walking ability, early identification of bone deterioration could preserve mobility and quality of life for thousands of affected boys worldwide.